Protein Folding and Misfolding on Surfaces by Stefani, Massimo
Int. J. Mol. Sci. 2008, 9, 2515-2542; DOI: 10.3390/ijms9122515 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms/ 
 
Review 
 
Protein Folding and Misfolding on Surfaces 
 
Massimo Stefani 
 
Department of Biochemical Sciences and Research Centre on the Molecular Basis of 
Neurodegeneration (CIMN), University of Florence, Florence, Italy. E-Mail: stefani@scibio.unifi.it; 
Tel. +39-055-4398307; Fax: +39-055-4398905 
 
Received: 6 November 2008; in revised form: 3 December 2008 / Accepted: 8 December 2008 / 
Published: 9 December 2008 
 
 
Abstract: Protein folding, misfolding and aggregation, as well as the way misfolded and 
aggregated proteins affects cell viability are emerging as key themes in molecular and 
structural biology and in molecular medicine. Recent advances in the knowledge of the 
biophysical basis of protein folding have led to propose the energy landscape theory 
which provides a consistent framework to better understand how a protein folds rapidly 
and efficiently to the compact, biologically active structure. The increased knowledge on 
protein folding has highlighted its strict relation to protein misfolding and aggregation, 
either process being in close competition with the other, both relying on the same 
physicochemical basis. The theory has also provided information to better understand the 
structural and environmental factors affecting protein folding resulting in protein 
misfolding and aggregation into ordered or disordered polymeric assemblies. Among 
these, particular importance is given to the effects of surfaces. The latter, in some cases 
make possible rapid and efficient protein folding but most often recruit proteins/peptides 
increasing their local concentration thus favouring misfolding and accelerating the rate of 
nucleation. It is also emerging that surfaces can modify the path of protein misfolding 
and aggregation generating oligomers and polymers structurally different from those 
arising in the bulk solution and endowed with different physical properties and 
cytotoxicities. 
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1. Introduction  
 
Increasing interest of protein science researchers is currently focussed at unravelling the molecular 
basis of protein folding and of its counterpart, protein misfolding and aggregation, as well as of the 
mechanisms of aggregate toxicity to living systems. The intense efforts spent in the past years to gain 
knowledge in these topics arise mainly from the awareness that it can shed light on the “folding code” 
built in most natural polypeptide chains as well as on the biochemical basis of a number of 
degenerative conditions that, at least in some cases, are of dramatic social impact [1-4]. The latter are a 
group of protein deposition pathologies including neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s and prion diseases, several systemic amyloidoses, type 2 diabetes, and others. Such 
diseases are characterized by the presence, in the affected tissues, of proteinaceous intracellular 
inclusions or extracellular deposits (amyloid plaques) whose main components are fibrillar aggregates 
arising from the polymerization of one out of around 30 proteins or peptides, each specific of a 
particular disease, that share basic structural features. Currently, it is believed that the aggregated 
material is the cause, rather than an epiphenomenon, of the clinical symptoms of the differing 
amyloidoses and that the latter, at least in the case of the neurodegenerative diseases, can ultimately be 
traced back to the cytotoxic effects of the aggregates [1-4].  
It is generally believed that protein folding and protein aggregation into amyloids are competing 
pathways relying on the same physicochemical principles (see later). Therefore, any increase of the 
information on the molecular features of protein folding can be useful to improve our knowledge on 
protein misfolding and aggregation and vice versa. Presently, it is widely accepted the idea that, 
similarly to protein folding, even the ability to polymerize into amyloid assemblies is a generic 
property of polypeptide chains inherently built in their peptide backbone and that its basic principles 
are shared by all aggregating peptides/proteins [4]. In particular, general consensus has been reached 
on the idea that protein/peptide aggregation starts from unstable, misfolded/unfolded states that 
initially assemble into disordered globular oligomers subsequently undergoing reorganization into 
beta-sheet-rich assemblies growing into ribbons and eventually into ordered fibrils [5]. However, 
recently, protein aggregation into fibrillar structures from natively folded states has also been reported 
(see below).  
Despite the large differences in the structures of the proteins and peptides aggregated in the 
assemblies found in the differing amyloidoses or produced in vitro, amyloid fibrils share basic 
structural features and an ordered core structure. A typical amyloid fibril is straight, unbranched, 6-12 
nm in width and reaches around 1 μm in length; it is formed by a variable number of elementary 
filaments (protofilaments) twisted around each other, typically 1.5-2.0 nm in diameter [6,7]. The main 
structural hallmark of amyloid fibrils is the ordered core of their protofilaments. The latter results from 
a double beta sheet which extends along the main filament axis and whose beta strands provided by 
each monomer stacks in register and run perpendicular to the fibril axis (what is known as cross-beta 
structure, whose signatures are the reflections at 4,8 and 9,6-11 Å in X-ray diffraction patterns) [8,9] 
(Figure 1). The recently described occurrence of amyloid fibrils with biological functions in several 
microbial and mammalian systems can lead to consider the amyloid fold among those occurring in the 
functional proteins rather than an aberrant protein structure [10]. 
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Figure 1. Outline of amyloid fibril structure. 
 
Amyloid fibrils are typically formed by two or more elementary protofilaments twisted around each 
other in a rope-like structure (left, AFM image). Each protofilament displays a shared ordered core 
structure where each monomer provides beta strands that stack in register forming a double parallel 
or antiparallel twisted beta sheet that propagates along the major axis of the fibrils whose beta 
strands run perpendicular to the fibril main axis (what is known as cross-beta structure, centre 
image). The X-ray diffraction signature of such structure (right image) are the reflections at 4,8 and 
9,6-11 Å provided by the regular distance between the stacked beta strands and the   
sheets, respectively. 
 
Increasing consensus has been reached in recent years on the identification of the most cytotoxic 
amyloids. Accordingly, the heterogeneous population of unstable fibrils precursors collectively known 
as protofibrils, or prefibrillar aggregates, are considered the most highly cytotoxic assemblies whereas 
amyloid fibrils are presently considered stable, relatively inert and harmless benign structures able to 
recruit the most toxic oligomers [4, 11-16]. Fibril precursor toxicity was confirmed by several findings 
showing that the appearance in tissue of small toxic oligomers precedes the expression of the clinical 
phenotype; this could explain the frequently observed lack of relationship between the load of fibrillar 
amyloid deposits and the severity of the clinical symptoms [17, 18]. These considerations have raised 
considerable interest on the structural features of these toxic intermediates, although their intrinsic 
instability and disorder make very difficult their structural characterization.  
The potential, as well as molecular mechanism of amyloid fibril nucleation and growth can be 
different in differing peptides and proteins as well as under varying medium conditions; however, in 
general, the onset of the process is triggered by any factor increasing the concentration of Int. J. Mol. Sci. 2008, 9 
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conformational states with high aggregation propensities, usually misfolded/unfolded species [4]. 
These conditions can favour thermodynamically protein aggregation, notably by reducing the 
conformational stability of the protein, as it can be the case of mutations, environmental changes or 
chemical modifications. Other factors can favour kinetically amyloid nucleation; this is the case of any 
increase of the amount of the protein/peptide following increased production, reduced clearance, or as 
a result of mutations with no effect on protein stability but able to increase the rate of oligomerization 
of the unfolded or partly folded monomers into aggregation nuclei (see later).  
Protein folding, but also misfolding and aggregation, in the biological environment can be 
differently affected by conditions such as the presence of high macromolecular concentrations or 
highly reactive molecules including reactive oxygen species and sugars that promote destabilising 
chemical modifications of proteins (oxidation, glycation). Moreover, the biological systems are 
characterised by the presence of extended surfaces. The latter include those specifically provided by 
the molecular chaperones favouring protein folding and others such as those provided by membranes 
and macromolecules. Actually, a natively folded protein or an unfolded peptide can undergo 
misfolding and structural reorganization with aggregate nucleation in the presence of suitable surfaces 
favouring non-native conformations with increasing tendency to aggregate (see later). 
Protein folding is subjected to a very intricate and precise quality control including the ER and 
cytosolic molecular chaperones, the ER membrane carriers performing the retrograde transport of 
proteins unable to fold in the ER lumen [19], the ATP-dependent proteolytic complexes in 
mitochondria [20], the components of the ubiquitin-proteasome pathway and two complex 
physiological responses such as the unfolded protein response and the heat shock response (reviewed 
in [21]). These mechanisms are aimed at hindering the appearance, in the cell, of any misfolded state 
potentially able to generate aggregation nuclei [4, 21] and are particularly efficient leading to 
degradation of around 30% of newly synthesized proteins [22]. Accordingly, protein aggregation can 
be favoured by the impairment or overwhelming of any of these molecular machineries. 
This review will present some of the most recent finding and ideas on some of the basic features of 
protein folding, misfolding and aggregation with special focus on the role performed by inorganic, 
organic and biological surfaces. 
  
2. Essentials of protein folding 
 
The protein folding problem has been a challenging issue shrouded in mystery for decades, until the 
development of the energy landscape theory. Actually it is not easy to understand how a polypeptide 
chain with an astronomical number of allowed conformations in its unfolded state is able to point to, 
and to reach with high precision, the native compactly folded structure in time lengths as short as 
milliseconds or fractions of seconds. 
If we take a simple 100 residue polypeptide chain and assume that each residue has only two 
allowed conformations, it results an overall 2
100, or 10
30, possible conformations of the whole 
molecule; this means that, at the concentrations used in a test tube folding experiment (i.e. around 10
18 
molecules) and the persistence times given by the molecular dynamics at room temperature (10
11 s
-1) 
each molecule in a given instant will exhibit a conformation different from that of any other molecule Int. J. Mol. Sci. 2008, 9 
 
2519
in the population. Yet, such an astonishing structural heterogeneity folds in very short times into a 
peculiar conformation endowed with a minimal conformational energy.  
The natively folded state of a protein cannot be reached by a systematic search among all the 
possible conformations accessible to its polypeptide chain, that would take an astronomical time, as 
stated by the Levinthal paradox [23]. Presently, there is general consensus on the view that the 
“folding code” of a polypeptide chain is entirely built into its amino acid sequence; therefore, the 
sequences of the natural proteins must have been shaped by natural selection in order to display some 
specific features exploiting the rapid molecular dynamics that allow specific residues, even those 
widely separated in the amino acid sequence, to come rapidly and reversibly in close contact with one 
another. The dynamics of the polypeptide chain of a natural protein in solution allow it to establish 
continuously native and non-native intramolecular contacts; however, the former are, on average, more 
stable, and hence more persistent. In addition, the establishment of those contacts is a cooperative 
process, meaning that these contacts are not mutually elusive but, rather, the conformational 
limitations provided by one of them favour other native contacts in a self-reinforcing process. Some of 
the native contacts organize, in times of the order of μs, key sites where elements of secondary 
structure are formed in a rudimentary native-like architecture and around which other contacts and 
elements of secondary structure are built. Finally, many experimental data on protein folding in vitro 
have shown that only a few contacts are enough to establish the “folding nucleus” of a protein; the 
latter primes the overall native topology of the condensed, still highly dynamic molten globule states, 
of the subsequent ensemble of the energy-rich but entropically restrained rate-limiting transition states 
(saddle points in the energy landscape, Figure 2) and, when present, of the folding intermediates. It can 
be concluded that a polypeptide chain finds its lowest energy structure by a trial and error stochastic 
process that samples only a very reduced conformational space and hence only a very small number of 
allowed conformations [24].  
The energetics of the folding behaviour of a polypeptide chain is best described by the energy 
landscape of an amino acid polymer. The energy landscape contains all conformational states 
accessible to the polypeptide chain together with their entropy, free energy and fraction of native 
contacts (Figure 2). These species are heterogeneous, highly dynamic and disordered conformational 
ensembles whose structures are far from the native one. The protein energy landscape is encoded in the 
amino acid sequence and, in the case of natural proteins, is robust (i.e. is not significantly affected by 
chemical modifications such as amino acid substitutions) and has the very special appearance of a 
rough funnel biased towards the native state [24,25]. Although it is not known yet how an amino acid 
sequence encodes its folding features, it is proposed that the key signature for a protein to fold 
correctly can be traced back to the pattern of hydrophobic and polar (notably charged) residues that 
favours preferential interactions of specific residues as the compactness of the structure progressively 
increases. Once these interactions have established the correct topology of the folding protein, the 
process evolves rapidly and invariably to generate the native compactly folded structure. Hence, for a 
polypeptide chain to fold efficiently into a specific three-dimensional structure, a suitable content and 
a specific pattern of hydrophobic and charged residues must be present. This is confirmed by the 
analysis of the natively unfolded proteins (NUPs) (see later), a set of natural proteins whose amino 
acid composition, providing a low mean hydrophobicity and a high net charge, makes them unable to 
fold in the intracellular environment [26]. Int. J. Mol. Sci. 2008, 9 
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Figure 2. Folding energy landscape. 
 
A schematic folding energy landscape displaying the evolution on a rather crude energy scale of a 
small protein from its unfolded ensemble (top) to the peculiar structure of the native state (bottom). 
The funnel-shaped graph biased toward the native state structure is a highly simplified model that 
recapitulates the changes in parameters such as the available conformational space of the folding 
molecule in terms of allowed residue contacts (entropy), the number of native contacts and the 
energy of the conformational ensembles. As the folding proceeds, there is a very rapid cooperative 
increase of the native contacts together with a reduction of either the conformational space that can 
be sampled for further contacts and the energy content. The surface funnels the highly 
heterogeneous multitude of the unfolded conformations  to the unique natively folded structure. 
The saddle region of the surface is a key point in this simple energy landscape corresponding to the 
transition state ensemble, the fraction of the molecules with the energy needed to cross the folding 
barrier. The transition state ensemble harbours molecular populations in which specific residues 
have established the key native-like contacts which determine the overall topology found in the 
native fold. For further details see under the text. 
 
Besides ensuring rapidity and precision, the above described behaviour acts as a folding quality 
control avoiding protein folding into altered states (misfolding) [25]. In fact, when, for some reason, 
the folding promoting interactions are not formed, the polypeptide chain fails to fold correctly and 
remains substantially unfolded thus avoiding that partially folded/misfolded structures can   
be generated. Int. J. Mol. Sci. 2008, 9 
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In conclusion, the current view describes natural proteins as a set of evolved amino acid polymers 
shaped by natural evolution in order to display secondary structure propensity and other 
physicochemical features such as mean hydrophobicity and net charge, as well as an overall energy 
folding landscape suitable to allow them to reach the unique compactly folded native structure 
efficiently and very rapidly avoiding the appearance of kinetic traps, energetically favoured non-
natively structured states that are set off-pathway of the folding process. The energy landscape theory, 
or “new view” of protein folding, based on statistical mechanics and polymer dynamics rather than on 
classic chemical dynamics, provides a conceptual framework to describe the general mechanism of 
protein folding and the rationale to design protein folding experiments and to interpret their results. 
 
3. Protein folding on surfaces 
 
Most of the present knowledge on protein folding arises from a multi-disciplinary approach 
including the use of a variety of simulation and experimental measurements carried out on wild-type 
and side-directed mutants of the investigated proteins. The experimental tools most widely used range 
from spectroscopic (CD, DLS, NMR), fluorimetric (fluorescence spectroscopy, FRET), diffraction 
(small angle X-ray diffraction scattering), mass spectrometry (MALDI-TOF coupled to limited 
proteolysis) and mutational (protein engineering) techniques to theoretical studies including molecular 
dynamics simulation and model building. However, these results, although of immense value, in 
general have been obtained in test tube experiments where a very simple environment was present 
(usually a buffer with a defined pH and ionic strength containing some co-solvent or denaturing agent). 
These conditions are very different from those found in the intracellular medium where protein folding 
takes place and lack the presence of other factors potentially affecting protein folding, misfolding  
and aggregation. 
The key signature of the intracellular milieu is its very high macromolecular concentration, 
averaging 300-400 mg/mL. This feature, often referred to as macromolecular crowding, has very 
important consequences in terms of thermodynamics affecting the conformational states of proteins 
[27]. A very high macromolecular concentration means that the volume freely available to a molecule 
is only a fraction of the total volume where the macromolecule is dissolved; therefore, the resulting 
excluded volume effects can favour thermodynamically compact states including both natively folded 
and aggregated states of proteins, though to a different extent depending on the protein. On this aspect, 
it has been calculated that an increase in macromolecular crowding from 30% to 33% (in terms of the 
volume of a given space occupied by molecules) could result in a rise of the molecular binding 
affinities by as much as one order of magnitude [27]. Such effects can also favour aggregate nucleation 
when proteins and peptides are unable to fold efficiently into monomeric compact states, although the 
increased viscosity of the medium can lower the diffusion-limited growth rate of the aggregation 
nuclei by reducing the translational movements of the macromolecules. 
One of the consequences of the intracellular macromolecular crowding is the presence, inside a cell, 
of a very large surface area including the overall macromolecular surface and that provided by the cell 
membranes. The latter can favour reversible unfolding/refolding of specific proteins when they 
physiologically translocate across the membrane [28]; some of the macromolecules found inside a cell 
can also favour protein folding be providing suitable surfaces. This is the case of the large and Int. J. Mol. Sci. 2008, 9 
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heterogeneous family of the molecular chaperones, including the prokaryotic GroES/GroEL and 
DnaK/DnaJ systems as well as many eukaryotic assemblies such as the Hsp70/Hsp40 system, other 
Hsp proteins and the crystallins. The role of these molecular chaperones is to provide a suitable 
environment, in most cases a surface, where a protein can fold rapidly and efficiently avoiding 
inappropriate interactions without being provided with any further information needed to find its 
native fold [29]. Actually, in most cases the molecular chaperones are able to specifically recognize 
exposed highly aggregation-prone segments avoiding their inappropriate interactions with other 
cellular components or with similar segments exposed on other protein molecules that could possibly 
result in aggregate nucleation. A recent survey in the protein data bank has shown that these highly 
aggregating stretches are most often capped by basic residues; such a feature, besides hindering the 
mutual interaction of these stretches that could enhance the generation of aggregation nuclei, also 
favours their recognition by molecular chaperones featuring co-evolution of the latter together with 
some structural features of proteins aimed at hindering their aggregation [30]. 
Another example of surfaces favouring protein folding is provided by the large family of the above 
mentioned NUPs [26]. These apparently structurally and functionally unrelated proteins include many 
transcription factors, ribosomal proteins and signalling proteins involved in the cell cycle control at the 
transcriptional and translational levels. Unstructured domains are also found in certain regions of other 
proteins that are otherwise natively folded. A recent search in the Swiss Protein Database has led to the 
prediction that over 15,000 proteins could contain disordered regions of at least 40 consecutive 
residues and over 1000 proteins could be completely disordered [31]. This observation indicates that 
significant segments of the eukaryotic genomes encode long stretches of amino acid residues that, at 
least under some conditions, are likely to be unfolded or to adopt non-globular structures of   
unknown nature.  
NUPs are usually easily recognizable from their amino acid content as they generally display a low 
mean hydrophobicity and a high net charge. These characteristics, thought to be the molecular basis by 
which these proteins remain unfolded in the absence of partners, are also able to reduce their intrinsic 
tendency to aggregate in the highly crowded intracellular milieu [32]. Here, the unstructured state of 
most NUPs favours their binding to the molecular chaperones during their short living time before they 
interact with their specific target proteins [26]. Actually, many NUPs adopt specific three-dimensional 
structures upon interaction with their specific target proteins that are thought to provide them a surface 
suitable to allow their folding [34]. It is also possible that the target protein provides some structural 
information needed for the specific NUP to reach its correct fold, in particular charged and 
hydrophobic residues complementing its structural deficiencies Alternatively, NUPs undergo rapid 
intracellular turnover by the cellular clearance mechanisms [33]. The latter feature could be an 
advantage for certain cellular functions, providing a further level of control to enable the cell to 
respond rapidly and effectively to perturbations in the cellular environment.  
 
4. Protein folding and aggregation are competing pathways 
 
Until 1998 it was commonly believed that the ability to polymerize into ordered fibrillar aggregates 
of amyloid type was a shared property of the few proteins and peptides found aggregated in tissue in 
the various amyloid diseases possibly arising from some structural peculiarity. However, in 1998 it Int. J. Mol. Sci. 2008, 9 
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was found that two proteins unrelated to any amyloid pathology were able to aggregate in vitro into 
fibrillar assemblies undistinguishable from the classical amyloid fibrils [35,36]. Since then, it has 
increasingly been recognized that the tendency to aggregate into amyloid assemblies is a general 
property of the peptide backbone of proteins and peptides. Such a tendency arises from the primordial 
tendency of polypeptide chains to self-organize into polymeric assemblies stabilized by hydrogen 
bonds between parallel or anti-parallel polypeptide stretches in the beta-strand conformation provided 
by the monomers. The resulting polymers display the ordered cross-beta structure that characterizes 
the amyloid fold (reviewed in [4]). This does not imply that the side chains of the polypeptide chain 
are not important; rather, they determine the environmental conditions under which the polypeptide 
chain can undergo aggregation. This view considers natural proteins as a group of evolved amino acid 
polymers whose the amino acid sequences disfavour aggregation whilst favouring folding into 
compact states resulting mainly from the tertiary interactions among the side chains that shield the 
peptide backbone. Conversely, protein aggregation into amyloid, which is mainly stabilized by 
secondary interactions, is considered the expression of the intrinsic primordial tendency of the peptide 
backbone to give secondary intermolecular interactions between backbone groups (reviewed in [4]). 
Another consequence of such a paradigm is that protein folding and protein aggregation must be 
distinct but competing pathways the same polypeptide chain can undergo depending on the 
environmental conditions (Figure 3). Accordingly, extensive studies have been carried out in vitro to 
investigate the transition between natively folded states and soluble aggregate-precursor states and 
between the latter and mature amyloid fibrils [37]. 
As it has been pointed out above, the intracellular macromolecular milieu is likely to favour 
compact states such as those arising from protein folding or protein aggregation. Moreover, protein 
folding and protein aggregation rely on similar physicochemical parameters of the polypeptide chain 
including a significant propensity to gain secondary structure, a low net charge, and a relatively high 
content of hydrophobic residues; these considerations are confirmed by the structural adaptations in 
the NUPs (see above) and by the data indicating that mutations increasing the mean hydrophobicity or 
the propensity to generate beta structure or reducing the net charge of any protein/peptide can 
accelerate its aggregation from an unfolded state [38]. These findings confirm that protein folding and 
protein aggregation are pathways in close competition to each other and that any polypeptide chain can 
undergo either pathway depending on both its structural and physicochemical features and   
medium conditions. 
The view that protein folding and aggregation are competing paths considers both as distinct yet not 
mutually excluding processes relying on a more general energy landscape including conformational 
states not involved in protein folding, yet potentially accessible to a polypeptide chain [39]. The two 
sides of the protein energy landscape highlight the competition between intramolecular (folding) and 
intermolecular (aggregation) interactions, which increases considerably the roughness of the whole 
landscape. The scheme depicted in Figure 3 (modified from [40]) suggests, at least in part, the 
complexity of the overall protein folding and aggregation energy landscape. It includes some of the 
main conformational states a polypeptide chain can get during its self-organization paths eventually 
culminating with the appearance of thermodynamically favoured compact monomeric or polymeric 
states [39]. Either stable final compact state may be even more favoured thermodynamically in a living 
cell by the macromolecular crowding and its excluded volume effects (see above). Int. J. Mol. Sci. 2008, 9 
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Figure 3. Combined protein folding/aggregation landscapes. 
 
A combined energy landscape model for protein folding (left) and aggregation (right) starting from 
the unfolded ensemble. Both sides display considerable roughness, but amyloid fibrils display a 
remarkably higher stability and lower energy content than the natively folded structure. The picture 
highlights the multitude of the different conformational states available to a protein when they are 
stabilized by either intramolecular (monomeric protein) or intermolecular (aggregation 
intermediates and mature fibrils) contacts. The presence of intermolecular contacts increases 
dramatically the ruggedness of the landscape for protein aggregation with respect to what is shown 
in the folding side. The picture highlights energy barriers that a monomeric polypeptide chain 
either unfolded or natively folded must overcome to gain access to the aggregation landscape 
generating aggregation nuclei, often the rate-limiting step of the aggregation process. The energy 
barriers can be lowered by the presence of suitable surfaces. For further details see under the text. 
(Modified from [40]). 
 
The generation of oligomeric aggregation nuclei is considered a key step at the onset of protein 
aggregation, accounting for the delay times of polymer appearance that are recorded by in in vitro 
protein aggregation experiments. However, at variance with protein folding, where in depth 
investigations carried out in the last decade have provided significant information on the structural 
features of folding intermediates and transition states, much less knowledge is currently available on 
the conformational states available to an aggregating polypeptide chain; the structural features, at the 
atomic level, of the oligomeric assemblies arising in the path of protein aggregation are substantially 
unknown as well. Extensive investigation on alpha-synuclein has shown that, in this case, the transient Int. J. Mol. Sci. 2008, 9 
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oligomeric species are rich in beta-sheet, expose hydrophobic clusters and display a partially folded 
structure [40, 41]. Actually, some of the energy minima in the aggregation side of the energy 
landscape are expected to be poorly defined due to the broad heterogeneity of unstable, rapidly 
interconverting oligomeric states endowed with comparable free energies. On the contrary, the energy 
minima of the much more structurally defined stable higher order species (protofibrils, protofilaments 
and mature fibrils) can be much more easily identifiable, even though fibrils with different 
morphologies and structural differences can be formed under different solution conditions [42]. For 
example, the stabilities, and hence the energy minima, of mature amyloid fibrils, and their structural 
variants, are expected to be more pronounced than those of their natively folded monomers 
considering the reduced molecular dynamics and the consistency of the ordered core structure of the 
fibrils. The nucleation-dependent polymerization mechanism of fibril growth, whose physical basis 
approaches that of the ordered assembly occurring in crystal growth, also supports fibril stability and 
represents a key difference between protein folding and aggregation.  
It is possible to shift a protein from the folding to the aggregation side of its energy landscape by 
modifying its structural features (mutations, truncations, amino acid chemical modifications) or the 
environmental conditions (temperature, pH, medium composition). Increasing the concentration of the 
specific protein/peptide can also result in aggregate nucleation when the level of the nucleation 
precursors exceeds a critical concentration (reviewed in [4]). In most cases, protein aggregation can be 
started in the presence of mildly destabilising medium conditions, such as mild shifts of the 
temperature or the pH or the presence of moderate amounts of denaturing agents or of co-solvents such 
as trifluoroethanol; the latter modifies the dielectric constant of the solution increasing the stability of 
the secondary contacts while reducing that of the tertiary ones [43-45]. Under these conditions, a 
folded protein populates partially unfolded states by opening its closely packed structure, thus 
exposing aggregation-prone regions normally buried into the hydrophobic core and the peptide 
backbone, that is shielded by the side chains in the compactly folded state. These partially unfolded 
structures can bear similarities to the folding intermediates [38, 46, 47] or to some of the near-native 
conformations in dynamic equilibrium with a folded protein. The link between native state dynamics 
and fibrillar aggregation of a protein has been highlighted in the case of lysozyme by mass 
spectrometry experiments [48]. In the lysozyme, the relative instability of the partially folded 
precursors is the driving force allowing them to re-organize into still poorly stable, and often 
thermodynamically disfavoured, transient aggregation nuclei rich in beta structure, established 
between stretches of polypeptide chains in the beta strand conformation [48].  
Nucleation is the rate limiting step of the aggregation process and occurs during the lag phase; its 
kinetics can depend on the protein and medium conditions, whereas subsequent nuclei elongation is 
thermodynamically favourable and proceeds until completion of fibril assembly. Spherical oligomers 
and other pre-fibrillar forms, including curvy protofibrils, can be formed instead of aggregation nuclei 
and appear to result from a nucleation-independent path in the absence of any lag phase [49-52]. In this 
case, it is not clear whether these forms are on-pathway, growing by direct binding of monomers, or 
off-pathway, representing dead-end intermediates [51, 53-55]. Studies on beta-2-microglobulin (b2-m) 
have provided information on this issue. It has been shown that, depending on protein structural 
features and medium conditions, b2-m exists in different aggregation states; for b2-m and other 
proteins, some of these states (oligomeric species and beaded protofibrils) are off-pathway products Int. J. Mol. Sci. 2008, 9 
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[42,51,56] arising from the polymerization of partially folded species retaining significant amount of 
native structure and involving some of the native beta strands [57]. The latter species are different 
from the oligomers appearing in the fibrillization path, which involve extensive structural 
rearrangement into the stable cross-beta structure of amyloid fibrils [52].  
 
Figure 4. Aggregate nucleation from unfolded or natively folded states. 
 
The nucleation of oligomeric pre-fibrillar aggregates is the key, as well as the rate-limiting, step in 
the path eventually culminating with amyloid fibril formation. Usually, the process is initiated by 
the misfolded fraction of protein/peptide molecules either in equilibrium with the compactly 
natively folded states or arising from protein destabilisation following mutations, chemical 
modifications or any alteration of the physicochemical features of the environment. Recently, it has 
been reported that, in some cases, protein aggregation can start from natively folded states 
organising into oligomers. The latter can further grow into native-like fibrils, as in the case of 
serpins or Ure2p or, alternatively undergo conformational rearrangement populating misfolded pre-
fibrillar aggregates. For further details see under the text. 
 
Almost no information is currently available on the energy barriers a folded or a partially unfolded 
protein must overcome to gain access to the conformational spaces allowing it to re-organize into 
aggregation nuclei; however, it is believed that these structural transitions can be favoured, among 
others, by surfaces (Figure 3). This is a key issue, considering that the intracellular environment Int. J. Mol. Sci. 2008, 9 
 
2527
provides an extremely large surface area. Actually, surfaces, either biological or synthetic, can enhance 
protein misfolding and speed aggregation (see below) besides favouring protein folding in special 
cases (see above). 
Finally, recent findings have shown that, at least in some cases, a protein can aggregate by initially 
populating monomeric or oligomeric states where it maintains substantially its natively folded 
structure before subsequently undergoing conformational rearrangements into amyloids (Figure 4). In 
addition to the natively folded beaded protofibrils of b2-m (see above), other proteins have been 
proposed to undergo ordered fibrillar polymerization retaining their native fold at least in the initial 
steps. These include tranthyretin, for which a model with direct stacking of natively folded monomeric 
subunits has been proposed [58], T7 endonuclease I [59], p13suc1 [60], and the serpins (reviewed in 
[61]), where a domain swapping mechanism has been depicted. A similar mechanism could also 
underlie the generation of native-like fibrils by the yeast prion Ure2p [62] and the first step of the 
amyloid aggregation  of the Sso acylphosphatase [63]. 
 
5. Surfaces can favour protein unfolding/misfolding 
 
As stated above, proteins are synthesized and fold in a very complex environment where they are in 
close contact with other molecules and with biological surfaces such as membranes and 
macromolecular assemblies favouring, in some cases, their correct folding. However, biological 
surfaces, notably lipid membranes, can also affect the conformation of the interacting proteins 
populating secondary structure-based aberrant states of the polypeptide chain [64,65] thus modifying 
lipid arrangement with possible membrane disruption [66,67]. Surfaces can also recruit protein 
molecules increasing their local concentration and/or their proximity to each other in a two-
dimensional environment (Figure 5). Both effects can result in enhanced tendency of proteins/peptides 
to undergo aggregation. Actually, pre-fibrillar assemblies can grow on nanoparticles [68], anionic 
surfaces such as mica, fatty acid and SDS micelles, and anionic phospholipid vesicles [69-71], 
synthetic phospholipid bilayers [72-78] and cell membranes [79,80], modifying membrane structure 
and permeability and impairing the function of specific membrane-bound proteins and signalling 
pathways [81,82]. These studies carried out mainly with synthetic surfaces, have prompted increasing 
interest on the role of surfaces in protein aggregation and on the relation of the latter to the membrane 
structure and lipid composition. 
The effects of a surface on protein misfolding and aggregation depend on the chemical features of 
the monomer, its folded or unfolded state, the way it interacts with the surface and the 
physicochemical properties of the latter, including its electrostatic potential and hydrophobicity 
(reviewed in [83]). In the case of lipid membranes, density of lipid packing, curvature, compactness, 
rigidity or fluidity can also be important in affecting the features of monomer/oligomer interaction. 
The physicochemical properties of the two-dimensional environment of a surface can be very different 
from those of the bulk aqueous phase. For monomer concentrations above 1 nM, surface adsorption 
reduces considerably the average distance among molecules respect to that in the three-dimensional 
bulk solution favouring monomer-monomer interactions, aggregate nucleation and insertion into the 
lipid bilayer [69, 73-78] (reviewed in [84, 85]) (Figure 5), eventually leading to membrane 
disorganization [65, 67]. In addition, the strong electrostatic field or the non-polar environment of Int. J. Mol. Sci. 2008, 9 
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heavily charged or hydrophobic surfaces, respectively, can modify the protein fold with exposure to 
the surface of regions that normally are associated with each other through electrostatic or hydrophobic 
interactions [85]. This view agrees with experimental data showing that surfaces can catalyze the 
formation of amyloid aggregates by a mechanism substantially different from that occurring in the 
bulk solution [69].  
 
Figure 5. Distribution of molecules in a 3D or a 2D space. 
 
Distribution of the molecules in a three-dimensional (A) or in a two-dimensional (B) space such as 
those provided by the bulk solution or by a surface, respectively. In a 3D space, the average 
distance between protein molecules is in relation to the cube root of the total number of molecules 
whereas in a 2D space this depends on the square root of the number of molecules. As a 
consequence, for concentrations above 1 nM the same number of protein molecules typically are 
much closer to each other in a two-dimensional space than in the corresponding three dimensional 
space. Therefore, surfaces can locally increase protein concentration favouring reciprocal 
interactions and speeding aggregate nucleation. For further details see under the text. 
 
In the adsorbed state, proteins/peptides are at the interface of two phases with different 
physicochemical properties, and protein residues are involved in interactions with surface-exposed 
functional groups that can favour non-native structural states. In particular, hydrophobic or charged 
surfaces may induce local or more extensive unfolding resulting in the opening of the closely packed 
structure; concomitantly, hydrophobic groups normally buried into the compactly folded native state 
are allowed to interact with hydrophobic clusters exposed on the surface without paying the energy 
penalty resulting from the exposure of the same residues to the aqueous environment (reviewed in 
[85]). As discussed above, these considerations apply to the behaviour of chaperones in assisting 
protein folding, to the target-induced folding of natively unfolded proteins as well as to the trafficking 
of protein molecules across membranes. In most cases, the interaction of a misfolded or unfolded 
species with a lipid membrane is likely to occur via a two-step mechanism involving the electrostatic 
interaction of the positively charged residues with negatively charged or polar lipid head groups with Int. J. Mol. Sci. 2008, 9 
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structural alteration; this is followed by the insertion of hydrophobic regions of the protein/peptide 
inside the bilayer (reviewed in [86]) where, in general, the hydrophobic interior favours structural 
changes  and secondary interactions resulting in enhanced tendency of proteins and peptides to 
aggregate, as it has been shown for the prion protein, the Abeta peptides and amylin [64-66, 87]. 
However, not only membrane surfaces can be involved in protein aggregation. For example, it has 
been proposed that b2-m aggregation can be favoured by monomer binding to the collagen triple helix, 
thus providing a possible explanation of the tissue-specificity of dialysis-related amyloidosis [88]; it 
has also been proposed that binding affinity fluctuations could influence the concentration of wild-type 
and N-truncated b2-m in the proximity of collagen fibers and hence their susceptibility to aggregation 
[89]. Finally, recent findings suggest that, in the presence of collagen, monomeric b2-m aggregates 
into amyloid fibrils sprouting from the surface of collagen fibres either in vivo and in vitro [90]. 
Glycosaminoglycans can also provide a surface suitable to promote growth of amyloid assemblies of 
gelsolin [91] and acylphosphatase [92]. In addition, other polyanions such as SDS and nucleic acids 
have been found to accelerate fibrillization of alpha-synuclein and the prion protein, respectively [70, 
93]. Finally, as stated above, clusters of anionic phospholipids have been shown to e enhance protein 
misfolding and aggregation [70-72] and preferentially recruit protein aggregates (see below). 
Biological membranes may also be important in amyloid fibrillogenesis as the primary sources of 
the aggregating peptide monomers. Membrane environment is of fundamental importance in regulating 
membrane protein degradation by specific membrane proteases such as the secretases or the protein 
convertases. This is best exemplified by the Abeta peptides resulting from APP processing [94], the 
ABri and ADan peptides resulting from BRI processing (reviewed in [82]), the medin, and gelsolin 
peptides arising from lactadherin and gelsolin proteolysis, respectively [95] (reviewed in [96]), as well 
as other peptides such as that arising from Pmel17 processing (reviewed in [96]).  
Conflicting data on the effect of membrane cholesterol on amyloid aggregate production and 
toxicity have been reported in the past years (reviewed in [97, 98]). On this aspect, the cholesterol-AD 
relation is paradigmatic (reviewed in [99]). The positive relationship between hypercholesterolemia 
and risk of sporadic AD is known since long time, however a mechanistic explanation for such 
association has not yet been provided. Yet, many data suggest a protective effect of membrane 
cholesterol against aggregate cytotoxicity [100]; in addition, a loss of cholesterol in brain leads to 
neurodegeneration and reduced levels of cholesterol are found in brains from AD patients [101]. 
Possible clues on the effect of cholesterol on amyloid generation and interaction at the membrane level 
can be given by lipid rafts, ganglioside- and cholesterol-enriched dynamic membrane microdomains 
harbouring many membrane proteins including APP and secretases (reviewed in [102]). The increased 
presence of APP and secretases in lipid rafts may provide, at least in part, a theoretical framework for 
the observed increased AD risk in hypercholesterolemic people (reviewed in [99]). On the other hand, 
conflicting results have highlighted that altered cholesterol content in neuronal membranes could 
favour the amyloidogenic or the non-amyloidogenic pathway of APP processing with increased or 
reduced Aβ40/42 production, respectively [103-105]. The generation of amyloidogenic peptides 
arising from membrane processing of other proteins (reviewed in [83, 96]) could be affected by 
membrane lipid composition as well. 
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6. Biological surfaces are primary sites of amyloid interaction and toxicity 
 
The question as to whether amyloid fibrils are toxic to cells by themselves or, rather, they are 
harmless, stable reservoirs of toxic precursors stems from long time. Actually, in some cases mature 
amyloid fibrils have been reported to impair cell viability [106, 107]; however, it is increasingly 
recognized that unstable oligomeric assemblies appearing in the path of fibrillization are endowed with 
the highest toxicity (reviewed in [4]) thus accounting for the lack of direct correlation between density 
of fibrillar plaques in the brains of Alzheimer’s disease patients and severity of their clinical symptoms 
[17]. Considering the difficulty to get structural information on the intermediates (protofibrils) 
preceding the appearance of mature fibrils (see above), much interest has recently been focused on 
their morphological features, as shown by electron or atomic force microscopy. The earliest 
protofibrils typically appear as globular assemblies 2.5-5.0 nm in diameter spontaneously organizing 
into chains and variously sized rings often comprising small “doughnuts” with a central 2-3 nm wide 
pore (amyloid pores) [11-16]. Such subpopulation of pre-fibrillar ring-shaped aggregates could 
account for amyloid toxicity, thus envisaging a basically common early biochemical mechanism of the 
latter through cell membrane permeabilization (reviewed in [86]) (see also below) in a way that 
resembles the mechanism of several microbial pore-forming toxins [108]. Channels or pores formed by 
pre-fibrillar amyloid aggregates have been described in vitro for a number of peptides and proteins 
associated or not-associated with amyloid disease (reviewed in [4]) and characterized primarily by 
recording ion currents across biological or reconstituted membranes [77]. “Doughnuts” or channel-like 
assemblies of pre-fibrillar aggregates of many peptides and proteins have also been observed by EM 
and AFM [11, 109-111]. 
Besides recruiting protein monomers favouring their misfolding and aggregation, surfaces, notably 
cell membranes, can also bind actively the unstable oligomeric assemblies preceding the appearance of 
mature amyloid fibrils. The importance of the relation between membrane lipid composition and the 
ability of early aggregates of peptides and proteins to bind to and to disassemble membranes has been 
extensively investigated. Many studies highlight the key role of either anionic surfaces and membranes 
containing anionic phospholipids; as specified above, the strong electrostatic field given by clusters of 
negative charges can favour protein unfolding and aggregate nucleation; however, clusters of negative 
charges can also be sites of preferential interaction with pre-fibrillar aggregates. Accordingly, it has 
been shown that pre-fibrillar assemblies interact with, and destabilise, synthetic phospholipid bilayers 
[73-76, 78, 112] (reviewed in [86]) and cell membranes [79, 80], modifying membrane permeability 
and impairing the function of specific membrane-bound proteins and signalling pathways [81]. The 
roles of cholesterol and gangliosides in modulating Abeta peptide generation and aggregation (see 
above) as well as membrane-aggregate interaction have also been extensively studied. Actually, it has 
recently been reported that pre-fibrillar aggregates supplemented to the cell culture media display 
reduced interaction with the cells and cytotoxicity upon enriching in cholesterol the cell membrane 
whereas the opposite effects were found in cholesterol-depleted cells [105, 113-115]. Although 
requiring more extensive research, these data support the idea that, in general, a higher membrane 
rigidity following increased cholesterol content can hinder aggregate interaction with the cell 
membranes thus enhancing membrane resistance against disassembly by the aggregates. Int. J. Mol. Sci. 2008, 9 
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Another question debated since long time is whether specific receptors for amyloids responsible of 
the amyloid-membrane interaction do exist on the cell membrane. The surface of the cell membrane is 
crowded of protein molecules. It has been estimated that the average plasma membrane surface is 
around 2,000 μm
2 with a density of membrane proteins averaging about 20,000 molecules/μm
2, for a 
total 40 x 10
6 protein molecules per cell surface. It is therefore conceivable that amyloid oligomers 
contacting protein molecules sprouting from the cell membrane may interact more or less specifically 
with some of them.  
In the past, several cell surface proteins have been considered as possible candidate receptors of Aβ 
aggregates. These receptors could be specific for the shared cross-beta fold rather than for any peculiar 
structural feature of the Aβ peptides although, in some cases, they could also be monomer-specific, as 
in the Aβ-APP or Abeta-TNFR1 interactions proposed to be at the origin of Aβ cytotoxicity [116, 
117]. Since 1996, the receptor for advanced glycation end products (RAGE) has been proposed as a 
major candidate as amyloid receptor [118]. RAGE is increased in systemic amyloidoses, is able to 
interact with amyloid assemblies made from serum amyloid A, amylin and prion-derived peptides 
[119] and appears involved in Alzheimer’s and Creutzfeldt-Jacob diseases [120, 121]. By competing 
for ligand binding with cell-surface RAGE, its plasma soluble form, sRAGE, might trap circulating 
ligands preventing their interaction with cell surface receptors. Actually, sRAGE appears protective 
against cytotoxicity of transthyretin aggregates [122] and its high plasma levels are associated with a 
reduced risk of several diseases including AD. Increasing plasma sRAGE is therefore considered a 
promising therapeutic target potentially preventing vascular damage and neurodegeneration [123].  
In addition to RAGE, several cell surface proteins, including voltage-gated [124] or ligand-gated 
calcium channels such as the glutamate NMDA and AMPA receptors have also been considered as 
possible receptors or specific interaction sites for amyloids [125-127]. In addition, tissue-type 
plasminogen activator (tPA) has also been proposed as a multiligand specific for the cross-β structure 
[128]. Finally, increasing evidence suggests that additional neuronal binding sites could be involved in 
the interaction with the plasma membrane of amyloid aggregates made from different peptides and 
proteins [129]; these could include anionic lipid clusters, as suggested by the finding that rising the 
content of negatively charged lipids results in increased channel formation by amyloids in synthetic 
lipid bilayers [66] and that annexin-5 protects against Aβ-peptide cytotoxicity by competing at 
common PS-rich sites [130]. 
The presence of specific effects mediated through the preferential, or even specific, interaction with 
membrane proteins could, at least in part, explain the variable vulnerability to amyloids of different 
cell types [113]. However, in spite of these and other data on specific interaction sites for amyloids, the 
tendency of early amyloid aggregates to interact with synthetic lipid membranes supports the idea that 
the interaction can be non-specific but, possibly, modulated by the membrane lipid content (see 
above); such an interaction can also be able, by itself, to impair cell viability by altering membrane 
structure and permeability. 
Since 1993 it was proposed the “channel hypothesis” of amyloid toxicity, whereby the toxic 
aggregates form non-specific pore-like channels in the membranes of the exposed cells [73] (reviewed 
in [86]). The proposal is now supported by studies carried out both on synthetic phospholipid bilayers 
and on cell membranes showing that the function of specific membrane proteins is impaired by the 
interaction with misfolded species or their oligomers (reviewed in [86]), [131]. For example, the size-Int. J. Mol. Sci. 2008, 9 
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dependent permeabilization of artificial vesicles by protofibrillar α-synuclein suggests that 
permeabilization may occur mainly as a result of a specific membrane perturbation via the formation 
of pores at least 2.5 nm in diameter coexisting with fibrils, raising the possibility that, at the conditions 
found in the cytoplasm, “pores” may be stable enough to be the true pathogenic species in Parkinson’s 
disease [12]. The ability of most amyloidogenic peptides and proteins to form “pores” in their 
aggregation path convincingly supports the idea that membrane permeabilization can result even in 
vivo from the presence of such species and be the key trigger of cell sufferance and death (reviewed in 
[132]). Should the channel hypothesis gain further experimental support and be extended to proteins 
and peptides associated with other amyloid diseases, then inhibition of “pore” production would 
represent a solid rationale in the search of molecules to be used in amyloid disease therapy. 
    The presence of toxic aggregates inside or outside the cells impairs a number of functions ultimately 
leading to cell death by apoptosis or, less frequently, by necrosis [12, 109, 133-138]. This is true even 
for aggregates formed from proteins not associated with amyloid disease, featuring cytotoxicity as a 
generic property of every amyloid aggregate possibly arising from their shared cross-beta structure 
(reviewed in [4]) [138]. In most cases, initial perturbations of fundamental cellular conditions such as 
redox status and free Ca
2+ levels appear to underlie the impairment of cell function induced by the 
aggregates [15, 110, 137, 139-144]. 
In general, intracellular oxidative stress in cells exposed to toxic aggregates has been related to 
some form of destabilisation of cell membranes resulting in the lack of appropriate regulation of 
membrane proteins such as specific enzymes, receptors and ion pumps [82]. Oxidative stress has also 
been considered, at least in part, a consequence of Ca
2+  entry into cells following non-specific 
membrane permeabilization by pre-fibrillar aggregates. The latter can result from structural 
modifications of the membrane following the interaction with the aggregates or their monomers (see 
above), from membrane lipid peroxidation or from chemical modification of membrane ion pumps 
(reviewed in [4]), [141, 145]. Increased levels of intracellular free Ca
2+ can stimulate the oxidative 
metabolism providing the ATP needed to support the activity of membrane ion pumps involved in 
clearing the excess Ca
2+. The resulting ROS elevation would, in turn, oxidize membrane pumps and 
their regulatory proteins resulting in further free Ca
2+ increase [146] with uncontrolled ingress of Ca
2+ 
into, and release of pro-apoptotic signal from, the mitochondria. Such a chain of events, possibly 
occurring even in old age, could explain the relationship between ROS, intracellular free Ca
2+ increase, 
mitochondrial damage and apoptosis described in cells exposed to toxic amyloid aggregates (reviewed 
in [4,81]), [85, 93, 147]. Recent data on the biochemical features possibly accounting for the different 
vulnerability of varying cell types exposed to the same toxic pre-fibrillar aggregates highlight 
significant correlations between cell resistance, cholesterol content, total antioxidant capacity and 
Ca
2+-ATPase activity [112]. 
 
7. Conclusions 
 
The work carried on in the last ten years has provided significant steps forward in the knowledge of 
how a polypeptide chain folds into the unique compact and biologically active protein structure. 
Increasing information exploiting new spectroscopic, imaging, computing and simulation techniques 
makes it likely that we are starting to unravel the protein folding code. This is expected to have Int. J. Mol. Sci. 2008, 9 
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important outcomes in many areas of genomics and structural biology, including a better knowledge of 
protein unfolding and aggregation. Actually, it has emerged that protein folding and protein ordered 
aggregation rely on the same physicochemical parameters thus stressing the key importance of the 
structural adaptations evolved in order to select amino acid sequences endowed with the lowest 
propensity to unfold and aggregate in the complex and crowded intracellular milieu. It also led us to 
consider that protein folding and aggregation are processes closely related with a shared energy 
landscape where different conformational states most often in equilibrium to each other can   
be populated.  
Finally, the increased knowledge on the fundamentals of protein folding, misfolding and 
aggregation enables us to better understand the effects, on these, of external factors, such as 
temperature, pH, mutations, chemical modifications, molecular crowding and surfaces. In particular, 
the latter are increasingly recognised as important elements affecting remarkably the behaviour of a 
polypeptide chain providing it an environment with special physicochemical features, most often very 
different from those encountered in the bulk solution. Increasing data on the roles of surfaces in 
protein folding, misfolding and aggregation highlight contrasting effects. Some surfaces, such as those 
resulting from protein evolution, are able to promote protein folding over aggregation, as in the case of 
the molecular chaperones and the specific targets of the natively unstructured proteins. However, in 
other cases synthetic or biological surfaces can favour protein misfolding and aggregation over normal 
folding, as it is shown by a number of experimental results carried out on synthetic phospholipid 
membranes or SDS micelles, inorganic surfaces such as mica, or macromolecules such as 
glycosaminoglycans, collagen and nucleic acids. In some cases, these researches have shed light on the 
possible factors favouring the aggregation of specific proteins such as b2m and on the tissue specificity 
of the deposition of its aggregates. 
In conclusion, it can be expected that the knowledge gained from protein folding and aggregation 
studies will give new insights into the nature of amyloid diseases and will help to provide a more 
rational basis for novel therapeutic strategies. 
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